Anatomic Pathology Market
Anatomic Pathology Market Size, Share & Industry Analysis, By Product & Services (Instruments, Consumables, Services), By Application (Disease Diagnosis, Drug Discovery & Development), By End User (Hospitals, Diagnostic Laboratories, Research Laboratories), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The Anatomic Pathology Market is experiencing robust growth, with a projected CAGR of 6.8% from 2024 to 2031. The market value is expected to rise from USD XX billion in 2024 to USD YY billion by 2031.
North America currently leads the market, driven by advanced healthcare infrastructure and high adoption rates of innovative diagnostic technologies. Key metrics include increasing prevalence of chronic diseases, rising demand for personalized medicine, and growing investments in healthcare research and development.
The Anatomic Pathology market is quickly expanding as a result of the rising prevalence of cancer and other chronic diseases, technical developments in diagnostic procedures, and a greater emphasis on early and accurate disease diagnosis. The integration of digital pathology and artificial intelligence is predicted to drive market expansion by allowing for more efficient and precise pathological assessments.
Anatomic Pathology Market Dynamics:
Market Trend: Digital Pathology and AI Integration Revolutionize Diagnostic Processes
The combination of digital pathology and artificial intelligence (AI) is changing the anatomic pathology landscape. This trend is distinguished by the digitisation of pathology slides and the application of AI algorithms for image analysis, resulting in increased diagnosis accuracy and efficiency. Remote consultations, easier case study sharing, and more collaborative diagnostic procedures are all possible with digital pathology systems.
Recent advances in whole slide imaging (WSI) technology have greatly expanded the potential of digital pathology systems. These developments enable pathologists to view and analyse high-resolution photographs of complete tissue samples, allowing for more comprehensive examinations. AI-powered image analysis technologies are being used to help pathologists spot minor abnormalities and quantify biomarkers, particularly in oncology applications.
The introduction of digital pathology and artificial intelligence is also solving the world's growing pathologist shortage. By automating mundane processes and allowing for remote diagnosis, these technologies help to relieve workload demands and enhance access to expert opinions, particularly in impoverished areas.
Market Driver: Rising Incidence of Cancer and Chronic Diseases
The rising frequency of cancer and other chronic diseases is a key driver of the Anatomic Pathology market. As the world population ages and lifestyle-related risk factors become more common, the demand for accurate and prompt pathology diagnostics grows. According to the World Health Organisation, cancer is the world's second biggest cause of death, with an anticipated 9.6 million deaths in 2018. This figure is expected to rise to 16.4 million by 2040.
Anatomic pathology is critical in cancer diagnosis, staging, and treatment planning. The expanding emphasis on personalised medicine and targeted therapies has increased the significance of thorough pathology examinations. For example, analysing biomarkers and genetic alterations in tumour samples is critical for determining the most successful oncology treatments.
Furthermore, the growing prevalence of chronic diseases such as cardiovascular ailments, neurological conditions, and autoimmune diseases is driving up demand for anatomic pathology services. These disorders frequently necessitate tissue samples and histological studies to accurately diagnose and track disease progression.
Market Restraint: Shortage of Skilled Pathologists and Technicians
Despite rising demand for anatomic pathology services, a dearth of trained pathologists and laboratory technicians poses a substantial barrier to market expansion. The intricate nature of pathological examinations necessitates substantial training and skill, and the education pipeline for new pathologists is straining to keep up with rising retirement rates and demand.
According to research by the College of American Pathologists, the number of practicing pathologists in the United States fell by 17.5% from 2007 to 2017. This tendency is shared by many other countries, resulting in a global lack of pathology expertise. The scarcity is especially severe in subspecialties like neuropathology and paediatric pathology.
Segment Overview:
The Services segment is expected to dominate the Anatomic Pathology market during the forecast period.
The Services section of the Anatomic Pathology market, which comprises diagnostic consultation services, is expected to be prominent throughout the forecast period. This segment's growth is primarily driven by the increasing complexity of pathological assessments, rising demand for specialised expertise, and the tendency of smaller healthcare facilities outsourcing pathology services.
Recent improvements in the Services category have centred on incorporating modern technology to improve diagnostic skills. For example, major anatomic pathology service providers are investing in digital pathology platforms and AI-powered diagnostic tools to improve accuracy and efficiency. These tools allow pathologists to analyse more cases in less time and provide remote consultations with specialists.
The COVID-19 pandemic has hastened the adoption of telepathology services, which enable remote diagnosis and reduce the need for physical specimen transportation. This change has not only shortened turnaround times but also increased access to expert opinions for healthcare facilities in remote or underdeveloped locations.
Furthermore, the expanding trend of personalised treatment has driven up need for specialised pathology services, particularly in oncology. Molecular pathology services, which entail the detection of genetic and molecular markers in tissue samples, are rapidly expanding. These services are critical for directing targeted medicines and immunotherapies in cancer treatment.
Regional Outlook:
North America is expected to dominate the Anatomic Pathology market during the forecast period.
North America's dominance in the Anatomic Pathology market may be ascribed to a number of reasons, including improved healthcare infrastructure, widespread use of breakthrough diagnostic technologies, and large investments in medical research & development. The United States, in particular, dominates the market because to its strong healthcare system, emphasis on early disease identification, and the presence of large market participants.
Recent advances in the North American Anatomic Pathology industry include the widespread use of digital pathology systems and AI-powered diagnostic tools. The United States Food and Drug Administration's licensing of whole slide imaging systems for primary diagnosis has been a major driver of digital pathology adoption in the region. Major healthcare organisations and academic medical centres are making significant investments in digital pathology infrastructure to increase diagnostic accuracy and efficiency.
The region has also seen substantial advances in precision medicine, particularly in oncology, which is boosting demand for sophisticated pathology services. The National Cancer Institute's Precision Medicine Initiative has accelerated research and development of molecular pathology tools, resulting in market growth.
Key statistics demonstrating North America's dominance include:
-
The US anatomic pathology market was estimated at $5.4 billion in 2024 and is expected to increase at a CAGR of 6.2% between 2024 and 2031.
-
As of 2023, around 70% of US hospitals and diagnostic laboratories had deployed or were in the process of deploying digital pathology technologies.
Recent advancements in Canada have also helped to strengthen the region's market leadership. The Canadian government's $1.5 billion investment in the Pan-Canadian Artificial Intelligence Strategy has accelerated the development of AI-powered healthcare products, such as enhanced pathology diagnostic tools. Several Canadian academic institutions and firms are developing AI algorithms for pathology picture processing, reinforcing North America's dominance in the worldwide Anatomic Pathology sector.
Competitive Intelligence:
The Anatomic Pathology market is characterised by fierce competition among prominent players, with both established medical technology businesses and creative startups competing for market share. Leading corporations are strengthening their market positions through technical innovations, strategic collaborations, and mergers and acquisitions.
Major competitors in the Anatomic Pathology industry have made significant investments in digital pathology and AI capabilities to improve their offerings. For example, Roche Diagnostics increased its digital pathology range by acquiring BioImagene and developing the VENTANA DP 200 slide scanner. Similarly, Philips Healthcare has achieved substantial advances in digital pathology with their IntelliSite Pathology Solution, which was FDA-approved for primary diagnosis in 2017.
The market has also seen more collaboration between diagnostic businesses and AI technology providers. For example, Leica Biosystems collaborated with Indica Labs to add AI-powered image analysis tools into their digital pathology platform, therefore improving pathologists' diagnostic capabilities.
In terms of market share, the top five competitors control almost 65% of the worldwide Anatomic Pathology market. However, the market is changing with the arrival of new players specialising in speciality areas like molecular pathology and digital pathology solutions. These entrepreneurs are taking on established vendors by delivering more innovative and specialised products.
Financial performance varies among significant participants, although larger medical technology corporations often report sustained revenue growth from their Anatomic Pathology departments. However, rising R&D spending in digital and molecular pathology technologies have pushed profit margins down.
Looking ahead, the competitive landscape is projected to change even further as digital pathology and AI-powered diagnostic technologies become more widely adopted. Companies who can successfully incorporate these technologies into their product portfolios while demonstrating substantial gains in diagnostic accuracy and efficiency are likely to acquire a competitive advantage in this rapidly expanding sector.
Analyst Opinion:
The Anatomic Pathology market is at a watershed moment, set for rapid development and innovation in the next years. The combination of digital technologies, artificial intelligence, and molecular diagnostics is opening up unprecedented prospects to transform pathology assessments and enhance patient outcomes.
One of the most intriguing topics in Anatomic Pathology is the advancement of AI-assisted diagnostic tools. These advanced systems have the potential to dramatically improve the accuracy and efficiency of pathological diagnosis, especially in cancer detection and categorisation. As these AI algorithms improve through machine learning and access to greater datasets, we may anticipate further adoption and integration into everyday pathology operations.
Another area of possible disruption is the emerging discipline of spatial biology and multiplex tissue analysis. These technologies enable the simultaneous investigation of many biomarkers within the spatial context of tissue architecture, resulting in a more complete understanding of disease processes at the molecular scale. This method holds great promise for enhancing personalised treatment in oncology and immunology.
However, it is vital to emphasise that the effective adoption of these advanced technologies is strongly dependent on the availability of high-quality tissue samples as well as standardised sample preparation and analysis techniques. As a result, there is an increasing demand for better tissue banking and biospecimen management techniques within the healthcare business.
To summarise, while obstacles exist, notably in terms of standardisation and the integration of new technology, the future of Anatomic Pathology appears bright. Organisations who can effectively negotiate these hurdles while leveraging the power of digital pathology, AI, and molecular diagnostics will be well-positioned to improve patient care and promote precision medicine.
Major Players:
-
Roche Diagnostics
-
Danaher Corporation
-
Thermo Fisher Scientific
-
Hologic, Inc.
-
Agilent Technologies
-
Becton, Dickinson and Company
-
PHC Holdings Corporation (Formerly Panasonic Healthcare)
-
Sakura Finetek USA, Inc.
-
Merck KGaA
-
Bio SB, Inc.
Key Developments:
-
In February 2024, Roche Diagnostics introduced an AI-powered digital pathology platform to help with cancer diagnosis and treatment planning.
-
In April 2024, Thermo Fisher Scientific purchased a molecular diagnostics firm to broaden its services in precision medicine and companion diagnostics for anatomic pathology.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Roche Diagnostics
5.2. Danaher Corporation
5.3. Thermo Fisher Scientific
5.4. Hologic, Inc.
5.5. Agilent Technologies
5.6. Becton, Dickinson and Company
5.7. PHC Holdings Corporation
5.8. Sakura Finetek USA, Inc.
5.9. Merck KGaA
5.10. Bio SB, Inc. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Digital Pathology and AI Integration Revolutionize Diagnostic Processes
6.1.2. Increasing Adoption of Telepathology Services
6.1.3. Advancements in Molecular Pathology Techniques
6.2. Market Drivers
6.2.1. Rising Incidence of Cancer and Chronic Diseases
6.2.2. Growing Demand for Personalized Medicine
6.2.3. Technological Advancements in Diagnostic Techniques
6.3. Market Restraints
6.3.1. Shortage of Skilled Pathologists and Technicians
6.3.2. High Costs Associated with Advanced Pathology Equipment
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT & SERVICES (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Instruments
7.1.1. Tissue Processing Systems
7.1.2. Microtomes
7.1.3. Slide Staining Systems
7.1.4. Others
7.2. Consumables
7.2.1. Antibodies
7.2.2. Kits & Reagents
7.2.3. Probes
7.2.4. Others
7.3. Services
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Disease Diagnosis
8.1.1. Cancer Diagnosis
8.1.2. Infectious Disease Diagnosis
8.1.3. Others
8.2. Drug Discovery & Development
8.3. Others
9. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospitals
9.2. Diagnostic Laboratories
9.3. Research Laboratories
9.4. Others
9.4.1. Academic Medical Centers
9.4.2. Contract Research Organizations
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Application:
-
Disease Diagnosis
-
Drug Discovery & Development
-
Others
By End User:
-
Hospitals
-
Diagnostic Laboratories
-
Research Laboratories
-
Others
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511